FREQUENT DISEASE RELAPSE AFTER WITHDRAWAL OF DENDRITIC CELLS IMPRINT PRO-INFLAMMATORY
GUT 2021;– duration of follow up = 21.1 months (IQR 11.1 relapse, 43.1% (19/44) required steroids and 88.6% (39/44) was lost when multivariate analysis was undertaken. Following – (comparator L1) CI 0.04 negatively associated with relapse at 1 year for patients with – 12 months, respectively. Concomitant use did not impact out- come at any timepoint, nor affect median treatment persis- tence with UST. Prior anti-TNF exposure was a negative predictor of clinical remission at one year, OR 0.32 (95% CI 0.12–0.81, p≤0.02), but there was no association with disease location, phenotype, presence of perianal disease or those with a smoking history.

Conclusions Ustekinumab is effective in the treatment of moderate-severe CD in a treatment refractory RW cohort. In keeping with trial data, prior anti-TNF exposure was a negative predictor of remission and concomitant IM use did not alter clinical or biological outcomes.

P104
FREQUENT DISEASE RELAPSE AFTER WITHDRAWAL OF INFlixIMAB IN IBD PATIENT WITH SUSTAINED REMISSION

Hannah Gordon*, Jennifer Murray, Falguni Tailor, Sean Goh, James O Lindsay. Royal London Hospital, Whitechapel, UK

Introduction In the UK, NICE guidance recommends annual review of biologics, with withdrawal of therapy in all patients in remission. This study retrospectively evaluates disease course following withdrawal of infliximab in IBD patients with sustained remission.

Primary Outcome Relapse free survival.

Secondary Outcomes Identification of predictors of relapse and evaluation of response to future therapy.

Methods

IBD patients from Royal London Hospital who ceased infliximab due to sustained remission were identified. The following information was obtained from electronic patient records: demographics, Montreal classification, immunomodulator use, clinician determined relapse, objective evaluation of disease activity within 3 months prior to treatment cessation and 6/12/18/24 months following cessation (CRP>5, calprotectin>50, endoscopic, radiological), steroid use at relapse, subsequent biologic use and outcome Analysis was undertaken for total IBD, CD and UC. Survival analysis and logistical regression was calculated using SPSS®.

Results 75 patients were identified. CD:UC = 43:32, F:M = 34:41, median age = 31.3 years (IQR 41.15–40.75), median duration of follow up = 21.1 months (IQR 11.1–44.2), Asian:Black:Caucasian:Unknown = 16:3:47:9. The median relapse free survival for CD was 12.4 months (IQR 10.4–14.4) and for UC was 18.2 months (IQR 10.5–25.9). Relapse rates for patients who had completed follow up for each time point are presented in table 1:

In univariate analysis, perianal disease and L3 disease were negatively associated with relapse at 1 year for patients with CD (perianal OR 0.87 CI 0.09–0.81 p=0.03 and L3 OR 0.18 (comparator L1) CI 0.04–0.87 p=0.03). However significance was lost when multivariate analysis was undertaken. Following relapse, 43.1% (19/44) required steroids and 88.6% (39/44) restarted a biologic, 69.2% (30/44) restarting infliximab. Of those who restarted infliximab, 56.7% (17/30) responded to standard therapy, with 10% (3/30) requiring dose escalation. 33.3% (10/30) required alternative therapy.

Conclusion Within 24 months of cessation 76.5% patients relapsed. The majority of these restarted a biologic. However, only 56.7% patients who restarted infliximab responded to standard dose. With additional costs of newer biologics and morbidity of disease flare and steroid use, routine withdrawal of TNF antagonists should only occur after careful consideration.
the impact of activation by DC on homing profile was not identical to RAR blockade: DC-activated T cells expressed significantly higher levels of integrins α4, β7 and β1.

Dual tropic β7+CLA+ cells were present in blood at low frequency amongst antigen experienced T-cells in from both healthy donors and patients with active IBD. This population were enriched for cells producing pro-inflammatory cytokines (IFNγ, IL-17, TNFα) compared with β7-CLA-, β7+CLA- and β7-CLA+ cells.

Conclusion DC derived signals promote CLA expression to generate dual tropic T-cells in vitro, likely in part by attenuating RARα signalling. Dual tropic cells were also identified in blood. The pro-inflammatory nature of this population supports a possible role in intestinal or cutaneous IBD.

P106 PREDICTION OF OUTCOME IN ACUTE SEVERE ULCERATIVE COLITIS – COMPARISON OF CLINICAL AND ENDOSCOPIC INDICES

Vipin Gupta*, Waled Mohsen, Alex Adams, Aidings Murphy, Dharshan Sathanathan, Sarah Cripps, Oliver Brain, Rebecca Palmer, Tim Ambrose, Bruce George, Alissa Walsh, Simon Travis, Jack Satsangi. Translational Gastroenterology Unit, John Radcliffe Hospital, Oudh, Oxford, UK

Introduction The management of ASC needs early characterisation of factors predictive of outcome to allow appropriate patient counselling and stratification for second-line therapy or surgery. Travis et al (1996) predicted colectomy rates during same admission on basis of Day 3 stool frequency and CRP. Dinesen et al (2010) suggested that the number of additional Truelove and Witts’ (TW) criteria (fever, tachycardia, anaemia or CRP elevation) on admission predict colectomy rates. Following this Corte et al (2015) shown that UCEIS at baseline predict adverse outcomes (need for rescue therapy, Colectomy and readmissions). We compared the predictive accuracy of TW criteria on admission with a validated endoscopic scoring system (UCEIS), and with accepted Day 3 criteria.

Methods Cases of ASC were retrospectively evaluated. Number of TW criteria, UCEIS, inpatient medical therapy, same admission outcome and follow up were recorded. Pre-specified endpoints included rescue therapy, colectomy during same admission and colectomy within 1 year of follow up.

Results Consecutive 131 admissions (117 patients) between 2015–9 were analysed. All satisfied modified TW definition of ASUC. Sixty-eight patients (58%) were female, index presentation 38 (29%), median age at presentation 40 years (16–76), median disease duration 1 year (1–43), median follow up 23 months (1–49). Seventy-one (54%) received rescue therapy (ciclosporin 35/71 and anti-TNF 36/71). Colectomy rates were 15% (19/131) during same admission and 26% (30/117) within 1 year of follow up. Outcomes were stratified...